Vitaros

Vitaros is an easy-to-use first choice alprostadil cream for patients with erectile dysfunction (ED).4,5

It has been formulated to help men with all levels of ED and other associated conditions such as diabetes and cardiovascular disease.1-4

The cream is applied directly into the opening of the urethra allowing men to comfortably resume sexual activity.1,5,6 Vitaros provides an alternative to men who cannot, or do not want to take tablets 2,7 and may not want to use uncomfortable needles or pellets.2

Prescribing Information and Adverse Event Reporting

Vitaros prescribing information can be downloaded via the icon. Alternatively the SmPC can be accessed via the EMC website.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Ferring Pharmaceuticals Ltd.
Tel: 0800 111 4126, Email: mailto:medical.uk@ferring.com

Vitaros

Product information

Product information

Vitaros is a rapidly acting, discreet drop of cream that is applied directly into the opening of the urethra.1,5,6 The cream combines the active ingredient alprostadil with the unique permeation enhancer dodecyl-2-N,N-dimethylamino propionate (DDAIP) enabling the cream to be absorbed at the application site.1,5,6

Vitaros delivers the alprostadil into the urethra meaning that men do not experience systemic side effects which are often associated with tablets – such as headaches or dizziness.8-11 Patients also do not experience scarring and pain associated with injections and pellets.12-15

Vitaros. A first choice alprostadil. It works from 5 to 30 minutes after administration 1,5

When correctly applied, Vitaros has demonstrated efficacy in improving erectile function in patients with ED compared to placebo with significant improvements in all parameters (IIEF-EF scores, SEP2 and 3, GAQ).1,6,16

Successful penetration attempts are achieved by the majority of patients from 5 to 30 minutes after administration.1,5,6 The unique permeation enhancer DDAIP allows alprostadil to be quickly absorbed into the blood vessels in the erectile tissues.

Learn More

Vitaros. A first choice alprostadil. It works when the cream is applied directly into the urethra2,5,16

Studies have shown that when administered correctly, ongoing use can be associated with increased efficacy.2,16

In a three-month study, Vitaros 300 μg achieved a clinically significant improvement in erectile function (measured by the Erectile Function domain scores of the IIEF).1,6,16

Significantly more men using Vitaros 300 μg experienced successful penetration (as measured by the Sexual Encounter Profile question 2 [SEP2]) and completion of intercourse with ejaculation (measured by SEP3) compared with placebo.1,6,16

Learn More

Vitaros. A first choice alprostadil. It is the only urethral alprostadil in a cream1,6,16

Vitaros may be appropriate for patients who are unable to take oral therapies.6,7 Vitaros has no interactions with food or alcohol, so patients can enjoy social environments without the need to plan ahead.6,7 All common adverse events with Vitaros are localised to the application site, and are generally mild and of short duration.2,5

ED patients may wish to practise using Vitaros on their own, so they can use it when they need it without the fuss of reconstitution or close supervision from you.5,12-15,17

Learn More

How to Use

Vitaros must be applied directly into the opening of the urethra with the easy-to-use applicator. 1,5,6Application only requires 6 simple steps.

Watch this video for an easy guide to applying Vitaros.

Learn More

Mode of Action

A premeasured amount of cream (100 mg) is applied locally into the opening of the urethra at the tip of the penis.5 The unique permeation enhancer DDAIP allows alprostadil to be quickly absorbed into the blood vessels in the erectile tissues.1,6

Are you a Health Care Professional?

The following information is intended for UK Healthcare Professionals (HCPs). It contains information about prescribing, plus relevant patient information.

UY/2407/2017/UK September 2017